Arcus Biosciences, Inc. (NYSE:RCUS) Shares Sold by New York State Teachers Retirement System

New York State Teachers Retirement System trimmed its position in shares of Arcus Biosciences, Inc. (NYSE:RCUS) by 3.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 90,543 shares of the company’s stock after selling 3,708 shares during the quarter. New York State Teachers Retirement System owned 0.10% of Arcus Biosciences worth $1,348,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in the company. FMR LLC increased its stake in shares of Arcus Biosciences by 6.9% during the third quarter. FMR LLC now owns 4,467,557 shares of the company’s stock worth $68,309,000 after acquiring an additional 286,766 shares during the period. Point72 Asset Management L.P. increased its stake in shares of Arcus Biosciences by 32.9% during the third quarter. Point72 Asset Management L.P. now owns 2,437,073 shares of the company’s stock worth $37,263,000 after acquiring an additional 603,222 shares during the period. Parkman Healthcare Partners LLC increased its stake in shares of Arcus Biosciences by 146.9% during the third quarter. Parkman Healthcare Partners LLC now owns 1,025,754 shares of the company’s stock worth $15,684,000 after acquiring an additional 610,219 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its position in Arcus Biosciences by 25.1% during the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 931,048 shares of the company’s stock worth $14,236,000 after buying an additional 186,750 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its position in Arcus Biosciences by 11.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 566,979 shares of the company’s stock worth $8,669,000 after buying an additional 59,536 shares during the period. 92.89% of the stock is currently owned by institutional investors and hedge funds.

Arcus Biosciences Stock Up 3.0 %

RCUS stock opened at $11.06 on Monday. The company’s 50 day simple moving average is $13.92 and its 200-day simple moving average is $15.56. The firm has a market capitalization of $1.01 billion, a PE ratio of -3.51 and a beta of 0.84. Arcus Biosciences, Inc. has a 12 month low of $10.63 and a 12 month high of $20.31. The company has a debt-to-equity ratio of 0.08, a current ratio of 5.24 and a quick ratio of 5.24.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on RCUS. Morgan Stanley lowered their target price on shares of Arcus Biosciences from $36.00 to $25.00 and set an “overweight” rating on the stock in a research report on Tuesday, February 18th. Bank of America lowered their target price on shares of Arcus Biosciences from $22.00 to $17.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 19th. HC Wainwright lowered their target price on shares of Arcus Biosciences from $20.00 to $18.00 and set a “neutral” rating on the stock in a research report on Tuesday, February 18th. Finally, Wedbush restated an “outperform” rating and set a $36.00 target price on shares of Arcus Biosciences in a research report on Thursday, November 7th. Two equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $29.50.

Insider Activity

In related news, CFO Robert C. Goeltz II sold 3,594 shares of the company’s stock in a transaction that occurred on Tuesday, December 31st. The shares were sold at an average price of $15.00, for a total transaction of $53,910.00. Following the transaction, the chief financial officer now owns 60,138 shares of the company’s stock, valued at approximately $902,070. This represents a 5.64 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 12.30% of the company’s stock.

About Arcus Biosciences

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.